Today we announced that our management team will be participating in the upcoming H.C. Wainwright & Co., LLC 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City. Learn more here: https://bit.ly/4beRuWp
X4 Pharmaceuticals’ Post
More Relevant Posts
-
$SGMT - Is downward rally decreasing: About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.9. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sagimet Biosciences recorded a loss per share of 2.66. The entity had not issued any dividends in recent years. https://lnkd.in/gf-y6mtn #stocks #stocktwits #thematic_portfolio
To view or add a comment, sign in
-
Kronox Lab Sciences IPO Listed at Premium of 21.29% at ₹164.95/share vs issue price of ₹136/share . . #kronoxlab #ipoallotment #iponews #ipoalert #stocks #shares #stockmarket #sharemarketindia #stockmarketindia #sharemarket #stockmarketinvesting #directusinvestments
To view or add a comment, sign in
-
Kronox Lab Sciences IPO Listing: Kronox Lab Sciences share price witnessed a robust debut on the bourses today, June 10, 2024. The stock listed at ₹164.95, a 21 percent premium to issue price of ₹136 on the NSE. Meanwhile, on the BSE, it debuted at ₹165, up 21.32 percent or ₹29 from the IPO price.
To view or add a comment, sign in
-
Michael Cembalest, JPM | The impact of underperforming 2020 and 2021 US IPOs “For IPO investors, some of the substantial gains from the prior decade were wiped out by a flurry of poorly performing IPOs" that were issued in the pandemic years. And that’s before including “the generally disastrous returns” on special-purpose acquisition companies. Some 90 percent of SPACs, "an unmitigated mess for investors", underperformed the equity markets by as much as 70 percent. #ipos #spacs #returns #tech #biotech #pharma #monetarypolicy #fiscalpolicy
To view or add a comment, sign in
-
Schott Pharma AG prices IPO Expected to start trading on Frankfurt Stock Exchange on September 28th, 2023 CHECK OUT MY BOOKS: STORY INVESTING https://lnkd.in/gxJgArX INVESTING: FROM SCIENCE TO ART https://lnkd.in/dsc7_sBT #schottpharma #ipo #investing #investment #investingstrategy #eventdriven #event #stocks #price #equity #equityresearch
To view or add a comment, sign in
-
Concord Biotech listed at a premium of 21% over the IPO price of Rs 741 on the exchanges in Friday's trade. On both NSE and BSE, the share debuted at Rs 900 apiece, a premium of Rs 159 as against the issue price. #Concordipo #concordbiotech #ipoalert #stocks #shares #stockmarket #sharemarket #stockmarketindia #sharemarketindia #stockmarketinvesting #directusinvestments
To view or add a comment, sign in
-
Concord Biotech listed at a premium of 21% over the IPO price of Rs 741 on the exchanges in Friday's trade. On both NSE and BSE, the share debuted at Rs 900 apiece, a premium of Rs 159 as against the issue price. #Concordipo #concordbiotech #ipoalert #stocks #shares #stockmarket #sharemarket #stockmarketindia #sharemarketindia #stockmarketinvesting #directusinvestments
To view or add a comment, sign in
-
I am getting a lot of questions about Invizyne, and that is very nice thank you, BUT as we just filed for IPO at Nasdaq I am only allowed to share what is in the SEC S1 application: https://lnkd.in/dWnMq3t6 Make sure to read the S1 form in its entirety, including all the valid disclaimers and risk factors, but when you have done that I think you will find the "Business Overview" page 34 very interesting and insightful in regards to the questions about what Invizyne is up to...
To view or add a comment, sign in
-
Our new report sheds light on trends in biotech listings in Hong Kong throughout 2023. While the market remains muted, the biotech ecosystem has performed fairly steadily year-on-year, and we are optimistic about what we see so far in 2024. If you are an investor or a biotech company contemplating a Hong Kong listing or anticipating a future listing, this report will help you understand the key features of Hong Kong Stock Exchange-listed biotech companies, how these companies compare to each other and to companies and listings from previous years, corporate governance aspects to observe, and how to prepare for a potential listing. You can InMail me here with questions. #hongkongcapitalmarkets #biotech #leadinglawyers
Listings of biotech companies on the Hong Kong Stock Exchange in 2023 were muted but remain steady in comparison to 2022. Our team in Hong Kong analyzed the key features of these companies and their listings, including status and maturity of a company at IPO, IPO size, corporate governance aspects and post-IPO performance. https://lnkd.in/e_vSiAcr Paloma Wang | Kai Sun | Anthony Pang | Martina To | Lillian Lian #capitalmarkets #regulatory #biotech #asiapacific
To view or add a comment, sign in
-
-
Kronox Lab Sciences IPO Listed at Premium of 21.29% at ₹164.95/share vs issue price of ₹136/share . . #kronoxlab #ipoallotment #iponews #ipoalert #stocks #shares #stockmarket #sharemarketindia #stockmarketindia #sharemarket #stockmarketinvesting #directusinvestments
To view or add a comment, sign in